Last Updated: 16 Sep 2024
Executive Summary
Regenxbio Inc. (RGNX) is a clinical-stage biotechnology company specializing in gene therapy products. The company has a market capitalization of $634.59 million. Despite strong analyst support, with 11 out of 12 analysts recommending a buy or strong buy, the company's financial performance has been weak, with negative earnings and margins. The stock price is currently trading at $12.84, within its 52-week range.
Company Overview
Regenxbio Inc. develops gene therapy products to address genetic defects and enable cells to produce therapeutic proteins or antibodies. The company's pipeline includes treatments for various conditions, including retinal diseases, neurodegenerative diseases, and cardiovascular diseases.
Fundamental Analysis
Revenue: Revenue for the trailing twelve months (TTM) was $89.04 million, showing a 11.6% growth year-over-year.
Earnings: The company reported a net loss of $226.02 million for the TTM, resulting in a negative EPS of $5.24.
Margins: Regenxbio's profit margin and operating margin were both negative, indicating that the company is not yet profitable.
Balance Sheet: The company has a book value of $7.06 per share and no long-term debt.
Technical Analysis
Technical Indicators: The stock price is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is at 42.48, indicating a neutral market sentiment.
Support and Resistance Levels: The stock has support at $10.49 and resistance at $28.80.
Short Term Outlook
In the short term, Regenxbio's stock price is likely to remain volatile due to its weak financial performance. The company needs to demonstrate progress in its clinical trials and improve its margins to gain investor confidence.
Long Term Outlook
The long-term outlook for Regenxbio is more positive. The company has a promising pipeline of gene therapy products, and the market for these treatments is expected to grow significantly in the coming years. However, the company will need to execute well on its clinical trials and achieve profitability to unlock its full potential.
Analyst Recommendations
Analysts are generally bullish on Regenxbio Inc. Of the 12 analysts covering the stock, 4 have a strong buy rating, 7 have a buy rating, and 1 has a hold rating. The average analyst target price is $38.08, implying a potential upside of 196.6%.
